Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced
unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC), including: Squamous
cell carcinoma OR Adenocarcinoma (including bronchoalveolar cell) OR Large cell anaplastic
carcinoma (including giant and clear cell) OR Poorly differentiated NSCLC No small cell
carcinoma No distant metastases Measurable or evaluable disease by chest x-ray, CT, or MRI
scan Tumors adjacent to vertebral body are eligible if all gross disease is in the
radiation boost field No pleural effusion(s) that are exudative, bloody, or cytologically
malignant No asymptomatic brain metastases by CT or MRI scan

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
expectancy: At least 12 weeks Hematopoietic: Granulocyte count at least 2,000/mm3 Platelet
count at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusion or epoetin alfa
allowed) Hepatic: Bilirubin less than 1.5 times upper limit of normal Renal: Creatinine no
greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: No
uncontrolled serious cardiac disease No active congestive heart failure, unstable angina,
pericardial effusion, or arrhythmia Pulmonary: FVC or FEV1 at least 50% Resting or
exercise SaO2 on room air at least 90% by pulse oximetry Other: Not pregnant or nursing
Negative pregnancy test Fertile patients must use effective contraception No active
concurrent malignancy within the past 5 years, except: Nonmelanomatous skin cancer
Carcinoma in situ of the cervix No serious medical or psychiatric illness that would
preclude compliance No active serious infection No concurrent clinically significant
peripheral neuropathy No prior significant allergic reaction to drugs containing Cremophor
(e.g., cyclosporine or vitamin K) No greater than 10% weight loss in the past 3 months

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy
No concurrent immunotherapy (during radiotherapy (RT) and RSR13 administration)
Chemotherapy: No prior systemic chemotherapy No concurrent chemotherapy (during RT and
RSR13 administration) Endocrine therapy: No concurrent hormonal therapy (during RT and
RSR13 administration) Radiotherapy: No prior radiotherapy to the thorax Surgery: At least
1 week since prior diagnostic thoracoscopy OR At least 3 weeks since prior thoracotomy and
recovered No prior total surgical resection Other: At least 3 weeks since other prior
investigational agents or devices No prior RSR13